Introduction: Breast cancer is the most common cancer in the Iranian female population, and the incidence of the disease is rising. Early detection in association with staging or grading the tumor is the most effective method to increase survival rates. Studies have revealed that cortactin overexpression may play a role in the final stages of tumor progression and affects invasion and cellular motility. The aim of this study is to evaluate cortactin gene expression among Iranian female patients with breast cancer. Materials and Methods: Samples belonging to 70 breast cancer patients were randomly selected from the Imam Khomeini tumor bank. Normal and tumor tissues were prepared and stored at −80˚C. Cortactin gene expression was evaluated by real-time PCR. Finally the data, along with demographic and clinical parameters, were analyzed using Prism 5.0 software, followed by t-test and ANOVA analysis. Results: Cortactin gene expression among tumor tissues increased 95.71% in comparison with normal tissues. A significant correlation between cortactin gene expression and lymph nodes' involvement (P = 0.0077) and tumor stage (P = 0.0030) was observed. However, tumor grade (P = 0.8598), tumor size (P = 0.3058), and patient's age (P = 0.4135) had no significant correlation with the gene's expression level. Discussion: This study demonstrated that the cortactin gene's overexpression in breast cancer may enhance lymph nodes' involvement. This study also found that the gene's expression was raised significantly in progressed stages of the cancer. Therefore, cortactin gene overexpression is an important factor indicating breast cells' invasion. Conclusion: The cortactin gene's expression level can be considered an accurate indicator for female breast cancer and also an appropriate biomarker for this cancer in clinical evaluations.
Introduction
At the beginning of the 20th century, with the brilliant medical developments that led to control of infectious disease, few could imagine that non-communicable diseases (NCDs) would offer the strongest clinical challenge in the next century. It is estimated that 38 million people die due to NCDs annually, and nearly three quarters of them (28 million) live in less-developed countries [1] . Cancer, a major public health problem worldwide, is currently the second-leading cause of death, causing over 8 million deaths a year, second only to cardiovascular diseases, and cancer is expected to surpass cardiovascular diseases as a cause of death within the next few years [2] . Due to population growth and the aging of the population, cancer rates are increasing. In addition, the general risk factors for NCDs, such as smoking, overweight, physical inactivity, and changing reproductive patterns in association with urbanization and economic development are raising cancer rates [3] . Lung cancer is the leading cause of cancer death among both sexes in developed countries, while breast cancer remains the most prevalent cause of death among females in less-developed countries [4] . In countries with powerful economies, thanks to developments in early detection methods and improved treatments, cancer incidence and mortality rates are decreasing [5] . However, the data demonstrate that in many countries of South America, Africa, and Asia cancer rates have been increasing, most likely due to lifestyle changes [6] [7] . Breast cancer is among the five most common cancers in Iranian women. Although Iranian women are familiar with the disease [8] , the incidence of breast cancer is rising; most Iranian females suffer from later developed stages (III or IV), and they are also relatively younger (about 10 years) than their Western counterparts [9] [10].
Breast cancer is a heterogeneous association of tumors that have different clinical, pathologic, and radiographic indications [11] . Ductal and lobular carcinomas are the two most common histologic types of invasive breast cancer [12] . In addition, breast cancer can be classified via different commonly-used methods, including staging the tumor through the TNM system [13] [14] , and grading the tumor through the Nottingham grading system, or the Scarf-Bloom-Richardson system [15] [16] . To reduce mortality rates and improve the patients' prognosis, early detection in association with staging or grading the tumor is used [17] .
The cortactin gene (CTTN) is located on the amplicon 11q13, which is often reported to be overexpressed in human cancers, such as breast and bladder cancers, and esophagus, epithelium, and hepatocellular carcinomas [18] [19] . Recent studies indicated that cellular motility increased, and no cell-to-cell cohesion was necessary for tumor progression. Cortactin is among the most important actin-assembling proteins [20] . Cortactin's ability to interact with cytoskeleton proteins via the SH3 domain makes it correlate with a variety of processes, such as endocytosis and cell migration.
This protein is also responsible for invadopodia formation. Cancer cells decompose the extra-cellular matrix through the invadopodia used for cell migration [21] . Cortactin phosphorylation, acetylation, and deacetylation have been demonstrated, which are assumed to be important for cancer progression [22] . Although cortactin's action within tumor progression is not clearly understood, it seems that high expression of CTTN correlates with patients' worse prognosis or disease relapse. This means that CTTN overexpression may play a role in the final stages of tumor progression. Studies also reveal that CTTN overexpression does not lead to morphological changes, and it does not affect proliferation but instead influences invasion and cellular motility [18] [23] .
In this study, we evaluated cortactin gene expression among Iranian female patients with breast cancer to determine the correlation between cortactin gene expression with tumor size, grade and stage and also patients' age.
Material and Methods
Population study and tissue specimens: Seventy female patients suffering from breast RNA isolation and cDNA synthesis: RNA extraction was performed using the TriPure Isolation Reagent Kit according to the manufacturer's instructions (Roche, Germany). RNA quantity analysis was approached spectrophotometrically. cDNA was synthesized using the PrimeScript RT Reagent Kit (Roshe, Mannheim, Germany) according to the manufacturer's instructions.
Sequences of CTTN and GAPDH mRNAs were obtained from the NCBI database, and the desired primers were designed utilizing Primer 3 software (Table 1) metastasis to other organs or areas of the body, such as the liver, brain, and bones, stage IV patients were excluded. In addition, due to the small size of the sample groups, stage I and stage II patients were merged into one group, and patients at stage III were considered a separate group. Based on results between CTTN gene expression and disease stage, a significant correlation was observed (Figure 2(b) ). However, tumor grade (Figure 2(c) ), tumor size (Figure 2(d) ), and patient's age (Figure 2(e) ) revealed no significant correlation.
Discussion
This study's results revealed that the cortactin gene's expression was increased in 95.71% of tumor samples. Cortactin is an action-binding protein. Its overexpression prevents cell junctions, facilitating tumor's spread [24] . Despite indications of cortactin's overexpression effects on carcinoma cell migration, invasion, and metastasis, its exact mechanism of action in cancer progression is not yet completely understood [25] .
In this study, evaluating cortactin gene expression and lymph nodes' involvement demonstrated that this gene's overexpression in breast cancer may enhance lymph nodes' involvement. In addition, the gene's expression was raised significantly at more progressed stages of cancer. In agreement with this study's results, Tsai et al. investigated the correlation of cortactin expression with gastric adenocarcinoma clinical parameters through immunohistochemical and tissue microarray analysis [26] . They determined that cortactin overexpression had a direct relationship with more progressed stages of that cancer.
In addition, Sang Jae et al. reported cortactin overexpression among 58% of nonsmall cell lung cancer patients [27] and cortactin overexpression was remarkably associated with other clinical factors, including tumor size, and lymph nodes' involvement.
Chen et al.'s 2011 survey of breast cancer patients, using immunohistochemistry and tissue microarray, revealed that 23.2% of the patients had low CTTN expression (+), 60.6% had moderate CTTN expression (++), and 16.2% indicated high levels of CTTN expression (+++). However, Chen et al. did not report a significant correlation between cortactin expression and age, tumor grade, lymph nodes' circumstances, or tumor stage, which could result from the cancer's heterogeneity [20] .
In other studies that evaluated cortactin gene expression among a variety of cancers, the gene's overexpression was in direct correlation with cancer cell invasion and proliferation capability. Subsequently, based on this study's results, it could be claimed that cortactin gene overexpression is an important factor in breast cells' invasion. However, no significant correlation was observed between the studied gene's expression and tumor grade or size. The small sample size used in this study may be the cause for this result. Higher expression of the gene among the patients belonging to the elder age group, however this result was not statistically significant.
Conclusion
According to the results of this study, the cortactin gene expression level can be consi-dered an indicator for female breast cancer and also an appropriate biomarker for this cancer in clinical evaluations. Subsequently, molecular inhibitors, including micro RNAs, can be designed to prevent the protein production by this gene and to restrict its action, and therefore the progression of breast tumors. Despite the valuable information garnered from this study, which improved our understanding of invasive behavior, metastasis mechanisms, and control methods for breast carcinoma cells, more studies are needed to carry these findings further.
